Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MGAM | O43451 | 7/20 | 0.54 |
| ▸ | GAA | P10253 | 7/20 | 0.54 |
| ▸ | SI | P14410 | 7/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650808 | 0.86 | MGAM (0.48) | HPSEKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL5651271 | 0.84 | MGAM (0.50) | HPSEKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL5652484 | 0.84 | HPSE (0.48) | HPSEKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL5650016 | 0.82 | MGAM (0.48) | HPSEKDM4ENPC1TP53RAB9A | |
| SCHEMBL5651444 | 0.81 | PRMT5 (0.59) | HPSEHTT | |
| SCHEMBL6585826 | 0.81 | HPSE (0.67) | HPSEKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL5652928 | 0.80 | HPSE (0.53) | HPSENPC1RAB9ASMN1; SMN2MGAM | |
| SCHEMBL5651985 | 0.78 | PRSS12 (0.54) | HPSEPTGDR2 | |
| SCHEMBL5651534 | 0.78 | HTT (0.52) | HPSEHTT | |
| SCHEMBL7945641 | 0.77 | MGAM (0.69) | HPSEKDM4ENPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | HPSE 3728/4885KDM4E 1605/4885NPC1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.